UPDATE 1-J&J to submit at least 10 medicines for approval by 2019

NEW YORK, May 20 (Reuters) - U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.